- Aequus Pharmaceuticals Inc. (AQS) agrees to an extension for its promotional service agreement with Sandoz on Tacrolimus IR to December 31
- Aequus began Canadian promotional efforts in 2016 for Sandoz’s generic Tacrolimus
- Aequus has achieved a four-year compound annual growth rate of almost 20 per cent for the Sandoz Tacrolimus brand
- Approved Clinical uses of Tacrolimus IR in Canada include prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants
- Aequus Pharmaceuticals Inc. (AQS) is 4.76 per cent trading at $0.10 per share as of 2:54 p.m. EST
Aequus Pharmaceuticals (AQS) has agreed to an extension of its promotional service agreement with Sandoz on Tacrolimus IR to December 31.
Aequus began Canadian promotional efforts in 2016 for Sandoz’s generic Tacrolimus.
Aequus has achieved a four-year compound annual growth rate of almost 20 per cent for the Sandoz Tacrolimus brand.
It achieved the rate through targeted awareness, value-added services, and customized support for both provincial and transplant centre stakeholders.
Approved Clinical uses of Tacrolimus IR in Canada include prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants.
It is also approved for the treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants.
Tacrolimus is to be used alongside adrenal corticosteroids and other immunosuppressive agents.
The safety and efficacy of the use of tacrolimus with sirolimus have not been established.
Physicians experienced in immunosuppressive therapy and management of organ transplants should prescribe tacrolimus.
Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources.
The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
Tacrolimus treatment is given for active rheumatoid arthritis in adult patients for whom disease-modifying anti-rheumatic drug therapy is ineffective or inappropriate.
Tacrolimus may be used as monotherapy or in combination with non-steroidal anti-inflammatory drugs or steroids.
However, the possibility of increased toxicity has not been fully explored.
Aequus Pharmaceuticals Inc. (AQS) is 4.76 per cent trading at $0.10 per share as of 2:54 p.m. EST.
